Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Raylex
- Development stage
- Unknown
- Lead developer
- Alto Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Raylex is a topical over-the-counter (OTC) nail-biting deterrent developed and marketed by Alto Pharmaceuticals. It is delivered via a pen applicator and contains a combination of denatonium (the world's bitterest substance) and citrus peel extract to discourage nail biting through aversion therapy. Additionally, the formulation includes biotin (vitamin B8) to promote healthy nail growth. Unlike traditional coatings, Raylex is designed to penetrate the nail surface. It is primarily indicated for the behavioral prevention of onychophagia (nail biting) in both adults and children.
- Brand names
- Raylex
- Other names
- Raylex (nail biting solution)
Beyond the preview
Go deeper on Raylex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Raylex.